Study S002337

A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT05051579
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 272
Start: 2021-09-29
Primary completion: 2022-08-25
Lead sponsor: Eli Lilly and Company
Conditions: Obesity; Overweight and Obesity
Interventions: DRUG:LY3502970; DRUG:Placebo
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:J2A-MC-GZGI; EUDRACT_NUMBER:2021-002805-88

Registered primary outcomes

Percent Change From Baseline in Body Weight in LY3502970 and Placebo [Baseline, Week 26]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0004295	Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes. Wharton S, Cardiovascular diabetology	2025	Other trial	PMID 40481478 DOI	cites ClinicalTrials.gov:NCT05051579; registry reference DERIVED:40481478
R0009553	Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Wharton S, The New England journal of medicine	2023	Randomized trial	PMID 37351564 DOI	cites ClinicalTrials.gov:NCT05051579; registry reference DERIVED:37351564